Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 18, 2025, titled "Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)".
Press Release Jan 18 2025
Filed with NSE · · 4 pages · English
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jan 07 2025
- Press Release Dec 19 2024
- Press Release Nov 12 2024
- Press Release Oct 23 2024
- Press Release Oct 17 2024
Later from Zydus Lifesciences
- Press Release Jan 22 2025
- Press Release Jan 26 2025
- Press Release Jan 30 2025
- Press Release Feb 05 2025
- Press Release Feb 12 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences